CNS Pharmaceuticals (CNSP) EBITDA (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly EBITDA came in at -$6.0 million in Q4 2025, down 87.06% YoY from -$46.3 million in Q4 2024, and down 84.0% on a QoQ basis from -$3.3 million in Q3 2025.
CNS Pharmaceuticals (CNSP) EBITDA (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of EBITDA data on file, last reported at -$6.0 million in Q4 2025.
- Quarterly EBITDA fell 87.06% year-over-year to -$6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$16.0 million (down 7.28% YoY) and the FY2025 annual result came in at -$16.0 million, down 7.28% from the prior year.
- EBITDA eased to -$6.0 million in Q4 2025, from -$3.3 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$2.4 million in Q2 2025 to a low of -$6.0 million in Q4 2025.
- A 5-year average of -$4.0 million and a median of -$3.7 million in 2021 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2021 — EBITDA plunged 89.62% — and 2025, when it surged 42.2%.
- Tracing CNSP's EBITDA over 5 years: stood at -$3.3 million in 2021, then plunged by 57.91% to -$5.1 million in 2022, then dropped by 4.77% to -$5.4 million in 2023, then jumped by 40.51% to -$3.2 million in 2024, then plunged by 87.06% to -$6.0 million in 2025.
- The last three EBITDA figures came in at -$6.0 million (Q4 2025), -$3.3 million (Q3 2025), and -$2.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | CNS Pharmaceuticals | 2.66 Mn | -4.54 Mn | - | -5.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.99 Mn |
| Sep 30, 2025 | -3.25 Mn |
| Jun 30, 2025 | -2.41 Mn |
| Mar 31, 2025 | -4.34 Mn |
| Dec 31, 2024 | -3.20 Mn |
| Sep 30, 2024 | -5.63 Mn |
| Jun 30, 2024 | -2.53 Mn |
| Mar 31, 2024 | -3.54 Mn |
| Dec 31, 2023 | -5.38 Mn |
| Sep 30, 2023 | -4.53 Mn |
| Jun 30, 2023 | -4.03 Mn |
| Mar 31, 2023 | -4.93 Mn |
| Dec 31, 2022 | -5.13 Mn |
| Sep 30, 2022 | -3.42 Mn |
| Jun 30, 2022 | -3.56 Mn |
| Mar 31, 2022 | -3.15 Mn |
| Dec 31, 2021 | -3.25 Mn |
| Sep 30, 2021 | -3.81 Mn |
| Jun 30, 2021 | -3.81 Mn |
| Mar 31, 2021 | -3.61 Mn |